Abstract: Aspects of the invention concern methods for detecting, identifying and evaluating tobacco and tobacco products to determine the potential that these compositions have to contribute to a tobacco-related disease. It is based, at least in part; on the discovery that exposure of pulmonary cells to smoke or smoke condensate obtained from tobacco or tobacco products induces double stranded breaks in cellular DNA, which were efficiently detected using assays that measure the presence, absence, or amount of phosphorylation of the histone, H2AX.
Type:
Application
Filed:
May 11, 2005
Publication date:
September 18, 2008
Inventors:
Anthony P. Albino, Ellen D. Jorgensen, Frank Traganos, Zbigniew Darzynkiewicz, Wendy Jin
Abstract: Aspects of the invention concern methods for detecting, identifying and evaluating tobacco and tobacco products to determine the potential that these compositions have to contribute to a tobacco-related disease. It is based, at least in part; on the discovery that exposure of pulmonary cells to smoke or smoke condensate obtained from tobacco or tobacco products induces double stranded breaks in cellular DNA, which were efficiently detected using assays that measure the presence, absence, or amount of phosphorylation of the histone, H2AX.
Type:
Grant
Filed:
May 11, 2005
Date of Patent:
February 16, 2010
Assignee:
Vector Tobacco, Inc.
Inventors:
Anthony P. Albino, Ellen D. Jorgensen, Frank Traganos, Zbigniew Darzynkiewicz, Wendy Jin
Abstract: Methods, reagents, and kits are provided that permit flow cytometric determination of the phosphorylation status of retinoblastoma susceptibility gene protein (pRB) in individual cells. Methods are described that permit the hypophosphorylated, active, form of pRB to be measured either as an absolute quantity or as a proportion of total cellular pRB. Further described are methods that permit pRB phosphorylation status to be correlated with cell cycle phase and with protein components of the cell cycle. Screening of chemical compounds for antiproliferative and antineoplastic activity using the flow cytometric assays is demonstrated. Reagent kits that facilitate the subject methods are also provided.
Type:
Grant
Filed:
September 29, 2004
Date of Patent:
July 4, 2006
Assignee:
Becton Dickinson and Company
Inventors:
Zbigniew Darzynkiewicz, Frank Traganos, Gloria Juan, Stefan Gruenwald
Abstract: Methods, reagents, and kits are provided that permit flow cytometric determination of the phosphorylation status of retinoblastoma susceptibility gene protein (pRB) in individual cells. Methods are described that permit the hypophosphorylated, active, form of pRB to be measured either as an absolute quantity or as a proportion of total cellular pRB. Further described are methods that permit pRB phosphorylation status to be correlated with cell cycle phase and with protein components of the cell cycle. Screening of chemical compounds for antiproliferative and antineoplastic activity using the flow cytometric assays is demonstrated. Reagent kits that facilitate the subject methods are also provided.
Type:
Grant
Filed:
February 24, 1999
Date of Patent:
November 23, 2004
Assignee:
Becton, Dickinson and Company
Inventors:
Zbigniew Darzynkiewicz, Frank Traganos, Gloria Juan, Stefan Gruenwald